Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Cellular therapy: donor lymphocyte infusion
Autore:
Peggs, KS; Mackinnon, S;
Indirizzi:
Univ Coll London Hosp, Dept Hematol, London WC1E 6HX, England Univ Coll London Hosp London England WC1E 6HX , London WC1E 6HX, England
Titolo Testata:
CURRENT OPINION IN HEMATOLOGY
fascicolo: 6, volume: 8, anno: 2001,
pagine: 349 - 354
SICI:
1065-6251(200111)8:6<349:CTDLI>2.0.ZU;2-R
Fonte:
ISI
Lingua:
ENG
Soggetto:
ALLOGENEIC BONE-MARROW; CYTOTOXIC T-LYMPHOCYTES; CHRONIC MYELOID-LEUKEMIA; GRAFT-VERSUS-HOST; CHRONIC MYELOGENOUS LEUKEMIA; LEUKOCYTE INFUSIONS; ADOPTIVE IMMUNOTHERAPY; RELAPSED LEUKEMIA; MULTIPLE-MYELOMA; IN-VIVO;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
51
Recensione:
Indirizzi per estratti:
Indirizzo: Mackinnon, S Univ Coll London Hosp, Dept Hematol, 98 Chenies Mews, London WC1E 6HX, England Univ Coll London Hosp 98 Chenies Mews London England WC1E 6HX
Citazione:
K.S. Peggs e S. Mackinnon, "Cellular therapy: donor lymphocyte infusion", CURR OPIN H, 8(6), 2001, pp. 349-354

Abstract

The dose escalation of chemoradiotherapy that is achievable with stem celltransplantation is often insufficient to eradicate malignancy, and an associated immune-mediated graft-versus-malignancy effect may be equally important for many diseases. The most directly compelling evidence for its presence is the efficacy of donor lymphocyte infusions in generating anti-tumor responses, particularly for relapsed chronic-phase chronic myeloid leukemia. Response rates and durability appear lower with myeloma and acute myeloid leukemia and myelodysplasia syndrome, and minimal with acute lymphoblastic leukemia. There is relatively little data on indolent lymphoid malignancies. Issues that remain to be resolved include the precise nature of the effector cells and their target antigens, the best strategies for separating graft-versus-malignancy from graft-versus-host disease (GVHD) and their effecton the durability of responses, and the role of adjuvant chemotherapy/cytokines. Similar issues surround routine combination with nonmyeloablative transplantation protocols and preliminary data suggests that GVHD may continue to provide a major obstacle. (C) 2001 Lippincott Williams & Wilkins, Inc.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 13/07/20 alle ore 07:14:29